Gathering the record
Relay is organizing the evidence and source boundaries.
GnRH peptide hormone
A hormone signal used for reproductive hormone testing and specialized fertility treatment.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Decades of human endocrine testing and pulsatile-treatment research establish predictable LH/FSH responses in defined settings.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Adverse effects and risks depend strongly on indication, sex, fertility context, delivery pattern, and product labeling; continuous and pulsatile exposure are not interchangeable.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceAdverse effects and risks depend strongly on indication, sex, fertility context, delivery pattern, and product labeling; continuous and pulsatile exposure are not interchangeable.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
Three women with hypothalamic amenorrhea received specialist-controlled pulsatile GnRH through a portable pump.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| Monitored ovulation-induction cycles | 5–10 micrograms per pulse | Every 90 minutes |
This small case series describes pump pulses, not one daily injection. Continuous exposure and arbitrary injection schedules have different physiology.
Pulsatile GnRH · three-patient ovulation-induction report Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published human research evaluated pump-delivered pulses in women with hypothalamic amenorrhea, a condition caused by missing upstream reproductive signaling.
Population: Women with hypothalamic amenorrhea
Design: Prospective randomized pulse-dose comparison
Mechanisms
Brief or pulsatile GnRH exposure can stimulate gonadotropin secretion, while continuous GnRH-pathway stimulation produces different physiology. Diagnostic and pulsatile-fertility evidence cannot be generalized to arbitrary schedules.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Established human endocrine evidence with product-, indication-, and delivery-pattern specificity.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
How any nonstandard formulation or delivery pattern compares with authorized products and validated pump-based regimens.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The treatment required a selected diagnosis, specialist monitoring, and a pump-based delivery system. Pulsatile fertility evidence cannot be transferred to arbitrary, brief, or continuous administration patterns. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Prospective randomized pulse-dose comparison
Women with hypothalamic amenorrhea
Endpoints were not fully described in the current record.
Pulsatile GnRH restored gonadotropin signaling and ovulation in selected patients with hypothalamic amenorrhea.
Study administration: Not stated in the current record.
Limitations: Specialized pump-based delivery and selected diagnosis; not generalizable to other contexts.
Three-patient case series
Women with hypothalamic amenorrhea
Endpoints were not fully described in the current record.
The report described ovulation and singleton pregnancies during specialist-controlled pulsatile treatment.
Study administration: Subcutaneous pump delivering 5–10 microgram GnRH pulses every 90 minutes
Limitations: Three patients without a randomized comparator cannot establish broad safety or comparative effectiveness.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 1743321 · DOI 10.1016/s0015-0282(16)54716-5
PMID 6354756 · DOI 10.1016/s0015-0282(16)47411-x